Ketogenic diet reduces hypoglycemia-induced neuronal death in young rats

Kelvin A Yamada1, Nicholas Rensing, Liu Lin Thio

  • 1Department of Neurology, Box 8111, Washington University School of Medicine, 660 South Euclid Ave, St Louis, MO 63110, USA. yamadak@neuro.wustl.edu

Neuroscience Letters
|June 25, 2005
PubMed

Insights

Hypoglycemia can harm the developing brain in diabetic children. Feeding young rats a ketogenic diet before hypoglycemic events protected their brains from neuronal death, suggesting a potential protective strategy.

Area of Science:

  • Neuroscience
  • Metabolic Disorders
  • Pediatric Endocrinology

Background:

  • Hypoglycemia is a significant complication of insulin therapy in diabetic children, potentially causing long-term cognitive deficits.
  • Previous research indicates that brief, repetitive hypoglycemia in 21-day-old rats (P21) leads to cortical neuronal death.
  • The developing brain can utilize ketone bodies, such as acetoacetate and beta-hydroxybutyrate, as alternative energy sources.

Purpose of the Study:

  • To investigate whether adapting the developing brain to ketone utilization via a ketogenic diet can mitigate neuronal injury during hypoglycemia.
  • To test the hypothesis that providing ketones during hypoglycemic episodes protects against brain damage.

Main Methods:

  • Weaning postnatal day 21 (P21) rats to either a standard diet or a ketogenic diet.
  • Subjecting these rats to insulin-induced hypoglycemia at P25.
  • Assessing neuronal death in the cortex following hypoglycemic episodes.

Main Results:

  • Rats weaned to a ketogenic diet and subjected to hypoglycemia at P25 exhibited significantly less cortical neuronal death compared to littermates on a standard diet.
  • This suggests that adaptation to ketone utilization enhances brain resilience against hypoglycemic injury.

Conclusions:

  • A ketogenic diet may protect the developing brain from hypoglycemia-induced neuronal injury.
  • This animal model offers insights into factors influencing brain vulnerability during hypoglycemic events in early life.

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Diabetic Ketoacidosis l: Introduction01:25

Diabetic Ketoacidosis l: Introduction

DefinitionDiabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus, characterized by a triad of hyperglycemia (blood glucose >250 mg/dL), ketonemia or ketonuria, and metabolic acidosis (arterial pH <7.30 and serum bicarbonate <18 mEq/L). It results from insulin deficiency combined with elevated levels of counterregulatory hormones—glucagon, catecholamines, cortisol, and growth hormone—leading to increased lipolysis, hepatic ketone production, and...
Diabetic Ketoacidosis ll: Pathophysiology01:22

Diabetic Ketoacidosis ll: Pathophysiology

Diabetic ketoacidosis (DKA) is a metabolic emergency characterized by hyperglycemia, ketonemia, and metabolic acidosis. It results from severe insulin deficiency and an excess of counterregulatory hormones, leading to uncontrolled lipolysis, ketogenesis, and widespread electrolyte and fluid disturbances.Pathophysiology The central event in DKA is a profound loss of insulin action. Without insulin, glucose uptake in insulin-dependent tissues is impaired, while hepatic glucose production...